Rain Therapeutics Inc (OQ:RAIN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 8000 Jarvis Avenue, Suite 204
NEWARK CA 94560
Tel: N/A
Website: https://www.rainthera.com
IR: See website
<
Key People
Avanish Vellanki
Chairman of the Board, Chief Executive Officer, Co-Founder
Robert Doebele
Co-Founder, Acting Chief Science Officer
Trevor Wolfe
Director of Corporate Finance
Vijaya Tirunagaru
Vice President, Head of Biology and Non-Clinical Development
Lucio Tozzi
Vice President, Head of Clinical Operations
 
Business Overview
Rain Therapeutics Inc. (Rain) is a clinical-stage precision oncology company. The Company is engaged in developing therapies that target oncogenic drivers. The Company's lead product candidate, RAIN-32 (milademetan) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2). It is being developed in patients with MDM2 amplified or overexpressed cancers. MDM2 inhibition is a treatment approach due to dose-limiting on-target hematologic toxicities. The initial development opportunity for RAIN-32 be in patients with MDM2-amplified tumors, beginning with well-differentiated/de-differentiated (WD/DD) liposarcoma (LPS) patients. Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. RAD inhibition leads to synthetic lethality in the DNA damage repair (DDR) pathway.
Financial Overview
For the fiscal year ended 31 December 2020, RainTherapeutics Inc revenues was not reported. Net lossincreased 93% to $21.1M. Higher net loss reflects PurchasedR&D Written Off increase from $0K to $5.2M (expense),Research and development expense - Bal increase of 35% to$9.6M (expense), FV Adjustments of Financial Investmentsincrease from $251K to $2M (expense).
Employees: 17 as of Dec 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): N/A
EBITDA (TTM): N/A
Net annual income (TTM): N/A
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 33,696,630 as of Apr 23, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.